What are the cardiovascular effects of low ferritin and the recommended management for iron deficiency?

Cardiovascular Physiology of Low Ferritin

Low ferritin causes subclinical left ventricular systolic dysfunction and impaired myocardial contractility, even in the absence of anemia, through mechanisms involving reduced oxygen delivery, impaired mitochondrial function, and direct myocardial structural changes.

Pathophysiological Mechanisms

Iron deficiency affects cardiovascular function through multiple interconnected pathways:

Direct Myocardial Effects

• Impaired contractility: Iron is essential for myocardial energy metabolism and mitochondrial function. Low ferritin levels directly compromise cardiomyocyte function, leading to reduced left ventricular global longitudinal strain (GLS) and strain rate (GLSR) 1.
• Subclinical dysfunction: Even without anemia (hemoglobin >12 g/dL in women), ferritin levels <28.5 ng/mL independently predict impaired LV systolic function with 76% sensitivity and 77% specificity 1.
• Structural changes: Iron deficiency causes structural and functional myocardial alterations that precede clinical heart failure 1.

Metabolic Consequences

• Mitochondrial dysfunction: Iron is a critical cofactor for oxidative phosphorylation and ATP production in cardiac myocytes.
• Reduced oxygen utilization: Impaired iron-dependent enzymes compromise cellular oxygen metabolism, independent of oxygen-carrying capacity.
• Exercise intolerance: Iron deficiency uniquely reduces exercise capacity through both reduced oxygen delivery and impaired skeletal muscle oxidative metabolism 2.

Clinical Significance in Heart Failure

Iron deficiency occurs in approximately 50% of heart failure patients and independently predicts worse outcomes 2, 3:

Prognostic Impact

• Increased mortality risk: Both low ferritin (<30 ng/mL) and high ferritin (>200 ng/mL in women, >300 ng/mL in men) are associated with 2-fold increased risk of incident heart failure over 21 years 4.
• Higher hospitalization rates: Iron deficiency predicts increased HF hospitalizations independent of anemia 2.
• Reduced functional capacity: Directly correlates with worse NYHA class and 6-minute walk distance 2.

Diagnostic Criteria in Cardiovascular Disease

The 2022 AHA/ACC/HFSA guidelines define iron deficiency as:

• Ferritin <100 ng/mL (absolute deficiency), OR
• Ferritin 100-300 ng/mL with transferrin saturation (TSAT) <20% (functional deficiency) 2, 3

Critical diagnostic nuances:

• TSAT <20% is the key predictor: Recent meta-analysis demonstrates that only patients with TSAT <20% benefit from IV iron therapy (RR 0.81 for cardiovascular death/HF hospitalization), while those with TSAT ≥20% show no benefit (RR 0.98, interaction p=0.05) 5.
• Ferritin alone is insufficient: Ferritin levels did not modify treatment response in subgroup analyses 5.
• Emerging evidence suggests TSAT <20% alone may be sufficient for diagnosis in heart failure, regardless of ferritin levels 6, 5.

Screening Recommendations

• Baseline assessment: All heart failure patients should be screened for iron deficiency at diagnosis 2, 3.
• Ongoing monitoring: Re-evaluate iron status 1-2 times annually and after any HF hospitalization 3.
• Simultaneous testing: Always measure ferritin AND TSAT together 3.

Management Approach

Intravenous Iron Therapy

For symptomatic heart failure patients (NYHA class II-IV) with iron deficiency, intravenous ferric carboxymaltose improves exercise capacity, quality of life, and reduces HF hospitalizations 2, 3:

Treatment algorithm:

1. Confirm iron deficiency with ferritin and TSAT
2. Exclude contraindications: Do not administer if hemoglobin >15 g/dL 3
3. Calculate total iron need based on hemoglobin and body weight:
   • Hb <10 g/dL: 500-2000 mg depending on weight
   • Hb 10-14 g/dL: 500-1500 mg depending on weight
   • Hb 14-15 g/dL: 500 mg regardless of weight 3
4. Administer ferric carboxymaltose in single doses of 500-1000 mg 3
5. Recheck ferritin and TSAT at 3 months, then 1-2 times yearly 3

Evidence base:

• FAIR-HF trial: Significant improvements in NYHA class, 6-minute walk test, and quality of life in 459 outpatients 2
• AFFIRM-AHF trial: 26% reduction in HF hospitalizations (RR 0.74,95% CI 0.58-0.94) in 1132 patients with EF <50% 2
• Benefits occur independent of anemia presence 2, 3

Oral Iron is Ineffective

Oral iron supplementation does not adequately replete iron stores in heart failure patients 2, 7:

• IRONOUT HF trial showed no improvement with oral iron 2
• Poor absorption and inadequate bioavailability in HF patients 2, 7
• Do not use oral iron for treating iron deficiency in heart failure 2

Common Pitfalls

1. Waiting for anemia: Iron deficiency causes cardiovascular dysfunction before anemia develops. Screen and treat based on ferritin/TSAT, not hemoglobin 2, 1.

2. Using ferritin alone: Standard laboratory "low ferritin" cutoffs (<30 ng/mL) miss functional iron deficiency. Always evaluate TSAT 3.

3. Prescribing oral iron: This is ineffective in heart failure and delays appropriate IV therapy 2.

4. Ignoring non-responders: Approximately 30-40% of patients do not respond to IV iron therapy; the mechanism remains unclear and requires further investigation 6.

5. Overlooking inflammation: In chronic kidney disease with inflammation, TSAT <20% is more predictive than ferritin for cardiovascular outcomes 8.

Population-Specific Considerations

In chronic kidney disease: TSAT ≤20% (independent of ferritin) associates with 2-fold increased risk of HF hospitalization and cardiovascular death (HR 2.13,95% CI 1.62-2.80), even after adjusting for hemoglobin 8.

In young women without anemia: Ferritin <28.5 ng/mL causes measurable subclinical LV dysfunction on speckle tracking echocardiography, suggesting earlier intervention thresholds may be warranted 1.